Myc-Related Mitochondrial Activity as a Novel Target for Multiple Myeloma

Mitochondria are involved in the development and acquisition of a malignant phenotype hematological cancers. Recently, their role pathogenesis multiple myeloma (MM) has been suggested to be therapeutically explored. MYC is master regulator b-cell malignancies such as myeloma, its activation known deregulate mitochondrial function. We investigated impact activity on distinct entities disease tested efficacy inhibitor, tigecycline, overcome MM proliferation. COXII expression, COX activity, mass, membrane potential demonstrated progressive increase features progresses. In vitro vivo therapeutic targeting using inhibitor tigecycline showed promising cytotoxicity monotherapy combination with frontline treatment bortezomib. Overall, our findings demonstrate how emerges transformation progression therapies these novel vulnerabilities.